3’-β-C-Ethynyladenosine
3’-β-C-Ethynyladenosine is an adenosine analog. Adenosine analogs mostly act as smooth muscle vasodilators and have also been shown to inhibit cancer progression. Its popular products are adenosine phosphate, Acadesine (HY-13417), Clofarabine (HY-A0005), Fludarabine phosphate (HY-B0028) and Vidarabine (HY-B0277). 3’-β-C-Ethynyladenosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
For research use only. We do not sell to patients.
- CAS No.: 180300-54-3
- Formula: C12H13N5O4
- Molecular Weight:291.26
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCRF-CEM | IC50 |
0.61 μM
Compound: 1
|
Cytostatic activity against human CEM cells after 72 hrs by Coulter counter method
Cytostatic activity against human CEM cells after 72 hrs by Coulter counter method
|
[PMID: 26965865] |
| CCRF-CEM | IC50 |
0.61 μM
Compound: 5; Eado
|
Antiproliferative activity against human CEM cells after 72 hrs by Coulter counter method
Antiproliferative activity against human CEM cells after 72 hrs by Coulter counter method
|
[PMID: 30098481] |
| HeLa | IC50 |
0.29 μM
Compound: 1
|
Cytostatic activity against human HeLa cells after 72 hrs by Coulter counter method
Cytostatic activity against human HeLa cells after 72 hrs by Coulter counter method
|
[PMID: 26965865] |
| HeLa | IC50 |
0.29 μM
Compound: 5; Eado
|
Antiproliferative activity against human HeLa cells after 72 hrs by Coulter counter method
Antiproliferative activity against human HeLa cells after 72 hrs by Coulter counter method
|
[PMID: 30098481] |
| KB | IC50 |
0.83 μM
Compound: EAdo(16)
|
In vitro tumor cell growth inhibitory activity against human nasopharyngeal KB cell lines
In vitro tumor cell growth inhibitory activity against human nasopharyngeal KB cell lines
|
[PMID: 8960561] |
| L1210 | IC50 |
0.69 μM
Compound: EAdo(16)
|
In vitro tumor cell growth inhibitory activity against mouse leukemia L1210 cell lines.
In vitro tumor cell growth inhibitory activity against mouse leukemia L1210 cell lines.
|
[PMID: 8960561] |
| L1210 | IC50 |
0.73 μM
Compound: 1
|
Cytostatic activity against mouse L1210 cells after 48 hrs by Coulter counter method
Cytostatic activity against mouse L1210 cells after 48 hrs by Coulter counter method
|
[PMID: 26965865] |
| L1210 | IC50 |
0.73 μM
Compound: 5; Eado
|
Antiproliferative activity against mouse L1210 cells after 48 hrs by Coulter counter method
Antiproliferative activity against mouse L1210 cells after 48 hrs by Coulter counter method
|
[PMID: 30098481] |
Chemical Information
-
CAS No. 180300-54-3
-
Molecular Weight 291.26
-
Formula C12H13N5O4
-
SMILES
OC[C@@H]1[C@](O)(C#C)[C@@H](O)[C@H](N2C=NC3=C2N=CN=C3N)O1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
Purity & Documentation
References
[1]. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. [Content Brief]
[2]. Man S, et al. Potential and promising anticancer drugs from adenosine and its analogs. Drug Discov Today. 2021 Jun;26(6):1490-1500. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)